Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian G Feagan

Showing results (261-270 of 464) with videos related to

Pageof 47
Sort By:
Gastroenterology|August 28, 2020
Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative ColitisKatherine Li, Colleen Marano, Hongyan Zhang, et al.
Journal of Crohn'S & Colitis|July 22, 2016
Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance StudiesOmoniyi J Adedokun, Zhenhua Xu, Colleen W Marano, et al.
Inflammatory Bowel Diseases|May 20, 2015
Briakinumab for treatment of Crohn's disease: results of a randomized trialRemo Panaccione, William J Sandborn, Glenn L Gordon, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|December 24, 2021
A Clinical Prediction Model to Determine Probability of Response to Certolizumab Pegol for Crohn's DiseasePavine L C Lefevre, Parambir S Dulai, Zhongya Wang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 12, 2022
Responsiveness of Magnetic Resonance Enterography Indices for Evaluation of Luminal Disease Activity in Crohn's DiseaseJurij Hanžel, Vipul Jairath, Christopher Ma, et al.
Gastroenterology|June 30, 2019
Challenges in the Pathophysiology, Diagnosis, and Management of Intestinal Fibrosis in Inflammatory Bowel DiseaseGeert D'Haens, Florian Rieder, Brian G Feagan, et al.
Gastro Hep Advances|April 7, 2025
Effect of Risankizumab Induction and Maintenance Therapy on the Rate of Hospitalization in Patients with Crohn's DiseaseBrian G Feagan, Remo Panaccione, Stefan Schreiber, et al.
Inflammatory Bowel Diseases|September 23, 2020
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 StudiesWilliam J Sandborn, Brian G Feagan, Silvio Danese, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 18, 2024
Mucosal Healing With Vedolizumab in Patients With Chronic Pouchitis: EARNEST, a Randomized, Double-Blind, Placebo-Controlled TrialVipul Jairath, Brian G Feagan, Mark S Silverberg, et al.
Med (New York, N.Y.)|October 5, 2024
Responsiveness of different disease activity indices in moderate-to-severe ulcerative colitisVirginia Solitano, Remo Panaccione, Bruce E Sands, et al.
Pageof 47

Showing results (261-270 of 464) with videos related to

Sort By:
Pageof 47
Gastroenterology|August 28, 2020
Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative ColitisKatherine Li, Colleen Marano, Hongyan Zhang, et al.
Journal of Crohn'S & Colitis|July 22, 2016
Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance StudiesOmoniyi J Adedokun, Zhenhua Xu, Colleen W Marano, et al.
Inflammatory Bowel Diseases|May 20, 2015
Briakinumab for treatment of Crohn's disease: results of a randomized trialRemo Panaccione, William J Sandborn, Glenn L Gordon, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|December 24, 2021
A Clinical Prediction Model to Determine Probability of Response to Certolizumab Pegol for Crohn's DiseasePavine L C Lefevre, Parambir S Dulai, Zhongya Wang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 12, 2022
Responsiveness of Magnetic Resonance Enterography Indices for Evaluation of Luminal Disease Activity in Crohn's DiseaseJurij Hanžel, Vipul Jairath, Christopher Ma, et al.
Gastroenterology|June 30, 2019
Challenges in the Pathophysiology, Diagnosis, and Management of Intestinal Fibrosis in Inflammatory Bowel DiseaseGeert D'Haens, Florian Rieder, Brian G Feagan, et al.
Gastro Hep Advances|April 7, 2025
Effect of Risankizumab Induction and Maintenance Therapy on the Rate of Hospitalization in Patients with Crohn's DiseaseBrian G Feagan, Remo Panaccione, Stefan Schreiber, et al.
Inflammatory Bowel Diseases|September 23, 2020
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 StudiesWilliam J Sandborn, Brian G Feagan, Silvio Danese, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 18, 2024
Mucosal Healing With Vedolizumab in Patients With Chronic Pouchitis: EARNEST, a Randomized, Double-Blind, Placebo-Controlled TrialVipul Jairath, Brian G Feagan, Mark S Silverberg, et al.
Med (New York, N.Y.)|October 5, 2024
Responsiveness of different disease activity indices in moderate-to-severe ulcerative colitisVirginia Solitano, Remo Panaccione, Bruce E Sands, et al.
Pageof 47